Date:1/31/2013

tementsThis press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q and Abaxis' other periodic reports filed
'/>"/>

SOURCE Abaxis, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Abaxis To Report Third Quarter Fiscal Year 2013 Financial Results Thursday, January 31, 2013
2. Abaxis Declares Special Cash Dividend of $1.00 Per Share
3. Abaxis, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference
4. Abaxis, Inc. to Participate in Sidoti & Companys Inaugural One-on-One Conference
5. Abaxis, Inc. to Present at the Stephens Fall Investment Conference
6. Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
7. Abaxis Announces Exclusive Distribution Agreement with Abbott
8. Abaxis Announces the Launch of Kidney Profile Plus Panel
9. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
10. Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 2012
11. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference